

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/260464 A1

(51) International Patent Classification:

C07D 471/14 (2006.01) C07D 241/36 (2006.01)
C07D 487/04 (2006.01) A61P 35/00 (2006.01)
C07D 495/14 (2006.01) A61K 31/429 (2006.01)
C07D 498/14 (2006.01) A61K 31/519 (2006.01)
C07D 513/14 (2006.01) A61K 31/5365 (2006.01)

(21) International Application Number:

PCT/CN2024/100794

(22) International Filing Date:

21 June 2024 (21.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/101669

21 June 2023 (21.06.2023) CN

(71) Applicant: REGOR PHARMACEUTICALS, INC.

[US/US]; 245 Main Street, Second Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: HUA, Xin; c/o Qilu Regor Therapeutics Inc.,

1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN). FENG, Teng; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN). WANG, Zhenglin; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN). WU, Tianlun; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN). YU, Bo; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN). ZHAO, Feng; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN). WANG, Kailiang; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN).

ZHONG, Wenge; c/o Qilu Regor Therapeutics Inc., 1206 Zhangjiang Road, Building C, Pudong New Area, Shanghai 201210 (CN).

(74) Agent: LIU, SHEN & ASSOCIATES; 10th Floor, Building I, 10 Caihefang Road, Haidian District, Beijing 100080 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PI3K INHIBITORS AND USE THEREOF

